

# Coronavirus Disease 2019 (COVID-19) Situation Report

Data as reported by national authorities by 24:00 local time 7 March 2021

Situation Report No. 243 - Kingdom of Bahrain  
8<sup>th</sup> of March, 2021



	Global		Eastern Mediterranean Region	
	COVID-19 Cases	COVID-19 Deaths	COVID-19 Cases	COVID-19 Deaths
<b>Total</b>	116,135,492	2,581,976	6,616,840	147,284
<b>New</b>	478,614	10,124	30,332	362


## Kingdom of Bahrain

	Confirmed Cases	Recovered Cases	Deaths	Active Cases	Critical Cases	PCR Tests
<b>Total</b>	126,602	119,771	472	6,359	61	3,194,226
<b>New</b>	476	724	3	-	-	14,715


## HIGHLIGHTS

- The Mortality were: 2 Bahraini citizens (1 male (83 years old) and 1 female (59 years old)) and 1 male expatriates (54 years old).
- Increasing number of citizens and residents continue to take COVID-19 Vaccine in Bahrain; and Ministry of Health (MOH) revealed the total number of individuals vaccinated as of 7 March 2021 for the first dose (308,465) and for the second dose (201,442).
- Ministry of Health (MOH) Undersecretary praised competence and dedication of the Bahraini health workers in confronting the Coronavirus pandemic.
- MOH Undersecretary indicated that priority in recruitment is given to the Bahraini volunteer health workers based on vacancies corresponding to their qualifications.
- Public Security Assistant Chief stressed individual responsibility in combating COVID-19, urging compliance with mandatory precautionary measures.
- Last month recorded the highest COVID-19 deaths ever since the onset of the pandemic in Bahrain.
- A study revealed that COVID-19 carriers in Bahrain who are asymptomatic are the 'silent spreaders' transmitting the virus at a high rate.
- A total of 45 people tested positive for COVID-19 after contact tracing of two infected individuals during random community screening.
- Multiple vaccines have been made available to achieve immunity and end the pandemic.
- Bahrain is piloting an internationally-recognized digital passport programme for global air travel.
- Over 80 government services have migrated to online last year due to the COVID-19 pandemic.
- Inmates in Bahrain can choose the vaccine they get.
- WHO: New research helps to increase understanding of the impact of COVID-19 for pregnant women and their babies; see link below.
- WHO: Guidance on Informing vaccination programs: a guide to the design and conduct of dengue sero surveys; see link below.
- WHO: Responding to non-communicable diseases during and beyond the COVID-19 pandemic; see link below.
- WHO: Emergency Global Supply Chain System(COVID-19) catalogue; see link below.
- WHO: Interim guidance on Antigen-detection in the diagnosis of SARS-CoV-2 infection using rapidimmuno assay; see link below.
- WHO: Global TB progress a trisk; see link below.
- WHO: SAGE values framework for the allocation and prioritization of COVID-19 vaccination; see link below.
- WHO: Interim guidance Operational considerations for COVID19 surveillance using GISRS; see link below.
- WHO: Statement by WHO Director of Programme Management on COVID-19 pandemic; see link below.
- WHO: As COVID19 spread accelerates JHR Emergency Committee urges focus on measures that work; see link below.
- WHO: The push for aCOVID-19 vaccine; see link below.
- WHO-ICMRA joint statement on the need for improved global regulatory alignment on COVID-19 medicines and vaccines; see link below.
- WHO Living Guideline: The rapapeuticsandCOVID-19; see link below.
- WHO: Interim guidance on Diagnostics, therapeutics, vaccine readiness, and other health products for COVID-19; see link below.
- WHO: Evidence to recommendations: COVID-19 mitigation in the aviation sector; see link below.
- WHO: Health workforce policy and management in the context of the COVID-19 pandemic response; see link below.
- WHO: Checklist to support schools re-opening and preparation for COVID-19 resurgences or similar public health crises; see link below.
- WHO: COVID-19 vaccine introduction and deployment costing tool; see link below.
- WHO: Emergency Use Designation of COVID-19 candidate vaccines: Ethical considerations for current and future COVID-19 place bo-controlled vaccine trials and trial unblinding; see link below.
- WHO: Considerations for implementing a risk-based approach to international travel in the context of COVID-19; see link below.
- WHO: Risk assessment tool to inform mitigation measures for international travel in the context of COVID-19; see link below.
- WHO: COVAX Announces additional deals to access promising COVID-19 vaccine candidates; plans global rollout starting Q1 2021; see link below.
- WHO: Rational use of personal protective equipment for coronavirus disease (COVID-19) and considerations during severe shortages; see link below.
- WHO issues its first emergency use validation for a COVID-19 vaccine and emphasizes need for equitable global access; see link below.
- WHO: Background document on the AZD1222 vaccine against COVID-19 developed by Oxford University and AstraZeneca; see link below.
- WHO: Rotavirus vaccines made available for use in humanitarian crises; see link below.


Number of New Cases



Total Number of Cases



Number of New Deaths



## IMPORTANT LINKS

- Daily COVID-19 updates on MOH website: <https://www.moh.gov.bh/>
- WHO's COVID-19 weekly situation reports: [https://www.who.int/docs/default-source/coronavirus/situation-reports/20200317-weekly-epi-update-1.pdf?sfvrsn=6d49a7e\\_4](https://www.who.int/docs/default-source/coronavirus/situation-reports/20200317-weekly-epi-update-1.pdf?sfvrsn=6d49a7e_4)
- WHO's COVID-19 Dashboard: <https://covid19.who.int/>
- WHO: New research helps to increase understanding of the impact of COVID19 for pregnant women and their babies: <https://www.who.int/news-room/detail/01-09-2020-new-research-helps-to-increase-understanding-of-the-impact-of-covid-19-for-pregnant-women-and-their-babies>
- WHO: Guidance on Informing vaccination programs: a guide to the design and conduct of dengue sero surveys: <https://www.who.int/publications/item/978-92-4-151258-9>
- WHO: Responding to non-communicable diseases during and beyond the COVID-19 pandemic : <https://bit.ly/2svd5dr>
- WHO: Emergency Global Supply Chain System(COVID-19) catalogue: [https://www.who.int/publications/item/emergency-global-supply-chain-system-\(covid-19\)-catalogue](https://www.who.int/publications/item/emergency-global-supply-chain-system-(covid-19)-catalogue)
- WHO: Interim guidance on Antigen-detection in the diagnosis of SARS-CoV-2 infection using rapidimmuno assays [bit.ly/2f0YjVf](https://bit.ly/2f0YjVf)
- WHO: Global TB progress a trisk <https://bit.ly/3d6u61n>
- WHO SAGE values framework for the allocation and prioritization of COVID-19 vaccination [bit.ly/2DwwWQ](https://bit.ly/2DwwWQ)
- WHO: Interim guidance Operational considerations for COVID19 surveillance using GISRS <https://bit.ly/34APNGG>
- WHO: Statement by WHO Director of Programme Management on COVID-19 pandemic <https://bit.ly/31059P>
- WHO: As COVID19 spread accelerates JHR Emergency Committee urges focus on measures that work: <https://bit.ly/372D06>
- WHO: The push for aCOVID-19 vaccine <https://bit.ly/3ms3h4a>
- WHO-ICMRA joint statement on the need for improved global regulatory alignment on COVID-19 medicines and vaccines: [bit.ly/3paxKSM](https://bit.ly/3paxKSM)
- WHO Living Guideline: The rapapeuticsandCOVID-19: <https://www.who.int/publications/item/therapeutics-and-covid-19-living-guideline>
- WHO: Interim guidance on Diagnostics, therapeutics, vaccine readiness, and other health products for COVID-19: [https://www.who.int/publications/item/WHO-2019-nCoV-h4Cf\\_assessment-Products-2020.1](https://www.who.int/publications/item/WHO-2019-nCoV-h4Cf_assessment-Products-2020.1)
- WHO: Evidence to recommendations: COVID-19 mitigation in the aviation sector: <https://www.who.int/publications/item/evidence-to-recommendation-covid-19-mitigation-in-the-aviation-sector>
- WHO: Health workforce policy and management in the context of the COVID-19 pandemic response: <https://www.who.int/publications/item/9789240017467>
- COVID-19 vaccine introduction and deployment costing tool: <https://www.who.int/publications/item/1066533753>
- WHO: Emergency Use Designation of COVID-19 candidate vaccines: Ethical considerations for current and future COVID-19 placebo-controlled vaccine trials and trial unblinding: [https://www.who.int/publications/item/WHO-2019-nCoV-Policy\\_Brief\\_EU\\_placebo-controlled\\_vaccine\\_trials-2020.1](https://www.who.int/publications/item/WHO-2019-nCoV-Policy_Brief_EU_placebo-controlled_vaccine_trials-2020.1)
- WHO: Considerations for implementing a risk-based approach to international travel in the context of COVID-19: <https://www.who.int/publications/item/WHO-2019-nCoV-Risk-based-international-travel-2020.1>
- WHO: Risk assessment tool to inform mitigation measures for international travel in the context of COVID-19: [https://www.who.int/publications/item/WHO-2019-nCoV-Risk-based-international-travel-Assessment\\_tool-2020.1](https://www.who.int/publications/item/WHO-2019-nCoV-Risk-based-international-travel-Assessment_tool-2020.1)
- WHO: COVAX Announces additional deals to access promising COVID-19 vaccine candidates; plans global rollout starting Q1 2021: <https://www.who.int/news/item/18-12-2020-covax-announces-additional-deals-to-access-promising-covid-19-vaccine-candidates-plans-global-rollout-starting-q1-2021>
- WHO: Rational use of personal protective equipment for coronavirus disease (COVID-19) and considerations during severe shortages: [https://www.who.int/publications/item/rational-use-of-personal-protective-equipment-for-coronavirus-disease-\(covid-19\)-and-considerations-during-severe-shortages](https://www.who.int/publications/item/rational-use-of-personal-protective-equipment-for-coronavirus-disease-(covid-19)-and-considerations-during-severe-shortages)
- WHO issues its first emergency use validation for a COVID-19 vaccine and emphasizes need for equitable global access: <https://www.who.int/news/item/31-12-2020-who-issues-its-first-emergency-use-validation-for-a-covid-19-vaccine-and-emphasizes-need-for-equitable-global-access>
- Background document on the AZD1222 vaccine against COVID-19 developed by Oxford University and AstraZeneca: <https://www.who.int/publications/item/20201222-vaccine-against-covid-19-developed-by-oxford-university-and-astrazeneca>
- WHO: Rotavirus vaccines made available for use in humanitarian crises: <https://www.who.int/news/item/04-03-2021-rotavirus-vaccines-made-available-for-use-in-humanitarian-crises>

## IMPORTANT CONTACTS

- The National Focal Person is Dr. Najat Mohamed Abulfateh, email: [NAI5@health.gov.bh](mailto:NAI5@health.gov.bh)
- International Health Regulations focal person is Dr. Kubra Salman, email: [knasser@health.gov.bh](mailto:knasser@health.gov.bh)